Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of AAV-hSMN1 (Vesemnogene Lantuparvovec) Gene Therapy in Subjects With Progressive Spinal Muscular Atrophy

NCT06288230 is registered in ClinicalTrials.gov with Lantu Biopharma as lead sponsor.

NCT NCT06288230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06288230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of AAV-hSMN1 (Vesemnogene Lantuparvovec) Gene Therapy in Subjects With Progressive Spinal Muscular Atrophy
Lead sponsor
Lantu Biopharma
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 20, 2024
Completion date
October 30, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy